Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.
André LacroixFeng GuJochen SchopohlAlbert KandraAlberto M PedroncelliLixian JinRosario PivonelloPublished in: Pituitary (2021)
NCT00434148.